Argatroban for anticoagulation during cardiac surgery

European Journal of Haematology

Volumn 78, Issue 2, 2007, Pages 161-166

  Martin, Monte E ^b   Kloecker, Goetz H ^b   Laber, Damian A ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NONE

Author keywords

Argatroban; Cardiopulmonary bypass; Cardiovascular surgical procedures

Indexed keywords

ARGATROBAN; WARFARIN;

ADULT; ANTICOAGULATION; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CASE REPORT; DRUG MONITORING; ENDOCARDITIS; HEART SURGERY; HUMAN; MALE; OFF PUMP SURGERY; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS; SURGICAL TECHNIQUE; THROMBUS; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; DRUG MONITORING; ENDOCARDITIS, BACTERIAL; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEPARIN; HUMANS; INTRA-AORTIC BALLOON PUMPING; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; MITRAL VALVE; PIPECOLIC ACIDS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SUBCLAVIAN VEIN; THROMBOSIS; VENOUS THROMBOSIS; WARFARIN; WHOLE BLOOD COAGULATION TIME;

EID: 33846051561     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00786.x     Document Type: Review

References (22)

1. Laber DA, Martin ME. Etiology of thrombocytopenia in all patients treated with heparin products. Eur J Haematol 2005;75:101-5.
2. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99:2530-6.
3. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
4. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003;101:31-7.
5. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003;75:577-9.
6. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
7. Cannon MA, Butterworth J, Riley RD, Hyland JM. Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77:711-3.
8. Edwards JT, Hamby JK, Worrall NK. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75:1622-4.
9. Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 2001;122:1255-6.
10. Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg 2004;78:e89-91.
11. Kamei M, Miyata S, Niwaya K et al. Successful argatroban- anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II. J Thromb Haemost 2003;1(Suppl. 1):P1162.
12. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000;14:445-57.
13. Kieta DR, McCammon AT, Holman WL, Nielsen VG. Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation.[see comment]. Anesth Analg 2003;96:956-8.
14. Ohno H, Higashidate M, Yokosuka T. Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery. Heart Vessels 2003;18:40-2.
15. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(Suppl. 5):489S-510S [erratum appears in Chest 1999;115:1760].
16. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
17. Welsby IJ, Stafford-Smith M. Monitoring direct thrombin inhibitors: time for standardization.[comment]. Anesthesiology 2004;101:1048-9.
18. Ohteki H, Furukawa K, Ohnishi H, Narita Y, Sakai M, Doi K. Clinical experience of Argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000;48:39-46.
19. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000;14:243-8.
20. Koster A, Spiess B, Chew DP, Krabatsch T, Tambeur L, DeAnda A, Hetzer R, Kuppe H, Smedira NG, Lincoff AM. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004;93:356-9.
21. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL II, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. [see comment]. J Thorac Cardiovasc Surg 2006;131:533-9.
22. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL 2nd, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006;131:686-92.